HEALTH● LOWAug 12 · Aug 12, 2026, 11:29 AM
Neurocrine slips as safety issues linked to Vykat XR resurface
Seeking Alpha Tech
Neurocrine's stock has declined due to resurfacing safety issues associated with its drug, Vykat XR. This indicates potential concerns for both the company's performance and patient health.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH26m agoHealth warnings could reduce youth’s hours spent on social mediaEuroNews [en]HEALTH58m ago14 fall ill after dining at Eaton HK hotel restaurantSouth China Morning PostHEALTH3h agoCan’t ask mosquitoes not to bite: Bengal Minister’s remark sparks criticismThe HinduHEALTH4h agoSuspected opioid overdose deaths rise as police issue new alert for Canberra | The Canberra Timescanberratimes.com.au · Australia